{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:34:29Z","timestamp":1778783669185,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2022-20-15"],"award-info":[{"award-number":["320.6750.2022-20-15"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104297"],"award-info":[{"award-number":["82104297"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Food and Chemical Toxicology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.fct.2023.114101","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T15:32:50Z","timestamp":1697643170000},"page":"114101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro"],"prefix":"10.1016","volume":"181","author":[{"given":"Sai-li","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiayan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanyong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianmeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaojie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-ping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-ai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fct.2023.114101_bib1","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/17425255.2017.1391213","article-title":"Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy","volume":"13","author":"Amsden","year":"2017","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.fct.2023.114101_bib2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0022-3565(24)29199-0","article-title":"Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos","volume":"299","author":"Dai","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.fct.2023.114101_bib3","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2147\/DDDT.S133814","article-title":"Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro","volume":"11","author":"Fang","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.fct.2023.114101_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/cpt.910","article-title":"The Pharmacogene variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database","volume":"103","author":"Gaedigk","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.fct.2023.114101_bib5","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"Gomez-Lopez","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.fct.2023.114101_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.fct.2023.114101_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109559","article-title":"Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro","volume":"345","author":"Han","year":"2021","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.fct.2023.114101_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41397-020-00179-4","article-title":"Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients","volume":"21","author":"Hannachi","year":"2021","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.fct.2023.114101_bib9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1345\/aph.1M393","article-title":"Drug-drug interaction between itraconazole and the protease inhibitor lopinavir\/ritonavir","volume":"43","author":"Hills-Nieminen","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.fct.2023.114101_bib10","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/prot.21123","article-title":"Comparison of multiple Amber force fields and development of improved protein backbone parameters","volume":"65","author":"Hornak","year":"2006","journal-title":"Proteins"},{"key":"10.1016\/j.fct.2023.114101_bib11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15358-5","article-title":"In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model","volume":"28","author":"Houston","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.fct.2023.114101_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2217\/pgs-2016-0179","article-title":"Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population","volume":"18","author":"Hu","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.fct.2023.114101_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3803\/EnM.2021.1349","article-title":"Interplay of vitamin D and CYP3A4 polymorphisms in endocrine disorders and cancer","volume":"37","author":"Kasarla","year":"2022","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"10.1016\/j.fct.2023.114101_bib14","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1097\/SLA.0000000000003455","article-title":"Targeting the hedgehog pathway using itraconazole to prevent progression of barrett's esophagus to invasive esophageal adenocarcinoma","volume":"273","author":"Kelly","year":"2021","journal-title":"Ann. Surg."},{"key":"10.1016\/j.fct.2023.114101_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10456-020-09758-2","article-title":"Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study","volume":"24","author":"Kroon","year":"2021","journal-title":"Angiogenesis"},{"key":"10.1016\/j.fct.2023.114101_bib16","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/jac\/dkx495","article-title":"Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir\/ritonavir in an HIV-infected patient with cerebral histoplasmosis","volume":"73","author":"Le Meur","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.fct.2023.114101_bib17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1124\/jpet.104.078758","article-title":"Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype","volume":"313","author":"Lee","year":"2005","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.fct.2023.114101_bib18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1517\/17425255.2013.794785","article-title":"Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections","volume":"9","author":"Lestner","year":"2013","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.fct.2023.114101_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bcpt.13246","article-title":"Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro","volume":"125","author":"Li","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.fct.2023.114101_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103288","article-title":"Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial","volume":"66","author":"Liesenborghs","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.fct.2023.114101_bib21","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1021\/acs.chemrestox.9b00100","article-title":"Characterization of genetic variation in CYP3A4 on the metabolism of cabozantinib in vitro","volume":"32","author":"Lin","year":"2019","journal-title":"Chem. Res. Toxicol."},{"issue":"4","key":"10.1016\/j.fct.2023.114101_bib22","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41401-021-00710-8","article-title":"Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers","volume":"43","author":"Liu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.fct.2023.114101_bib23","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2147\/DDDT.S312310","article-title":"Multiple administrations of itraconazole increase plasma exposure to pyrotinib in Chinese healthy adults","volume":"15","author":"Liu","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.fct.2023.114101_bib24","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.fct.2023.114101_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01245-19","article-title":"Impact of triazole therapeutic drug monitoring availability and timing","volume":"63","author":"McCreary","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.fct.2023.114101_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1439-0507.1994.tb00281.x","article-title":"Comparison of in vitro antifungal activity of itraconazole and hydroxy-itraconazole by colorimetric MTT assay","volume":"37","author":"Mikami","year":"1994","journal-title":"Mycoses"},{"key":"10.1016\/j.fct.2023.114101_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/45.3.371","article-title":"Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro","volume":"45","author":"Odds","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.fct.2023.114101_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00008571-200007000-00001","article-title":"Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method","volume":"10","author":"Ozdemir","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.fct.2023.114101_bib29","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1111\/bph.15418","article-title":"Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro","volume":"178","author":"Schloer","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.fct.2023.114101_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/22221751.2018.1559709","article-title":"The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo","volume":"8","author":"Schloer","year":"2019","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.fct.2023.114101_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/jcc.21922","article-title":"Quantum mechanically derived AMBER-compatible heme parameters for various states of the cytochrome P450 catalytic cycle","volume":"33","author":"Shahrokh","year":"2012","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.fct.2023.114101_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40262-014-0139-0","article-title":"Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications","volume":"53","author":"Stockmann","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.fct.2023.114101_bib33","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.fct.2023.114101_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/0091270010365885","article-title":"Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren","volume":"51","author":"Tapaninen","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.fct.2023.114101_bib35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/17425255.2014.883379","article-title":"Clinically relevant drug-drug interactions between antiretrovirals and antifungals","volume":"10","author":"Vadlapatla","year":"2014","journal-title":"Expert. Opin. Drug Met"},{"key":"10.1016\/j.fct.2023.114101_bib36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/17425255.2014.883379","article-title":"Clinically relevant drug-drug interactions between antiretrovirals and antifungals","volume":"10","author":"Vadlapatla","year":"2014","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.fct.2023.114101_bib37","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1002\/jmv.26917","article-title":"In vitro activity of itraconazole against SARS-CoV-2","volume":"93","author":"Van Damme","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.fct.2023.114101_bib38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.fct.2023.114101_bib39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bcpt.12934","article-title":"Functional characterization of 22 CYP3A4 protein variants to metabolize ibrutinib in vitro","volume":"122","author":"Xu","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.fct.2023.114101_bib40","doi-asserted-by":"crossref","first-page":"38091","DOI":"10.1074\/jbc.C400293200","article-title":"The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution","volume":"279","author":"Yano","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.fct.2023.114101_bib41","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/bmc.1186","article-title":"Bioanalytical methods for the determination of itraconazole and hydroxyitraconazole: overview from clinical pharmacology, pharmacokinetic, pharmacodynamic and metabolism perspectives","volume":"23","author":"Yao","year":"2009","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.fct.2023.114101_bib42","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/chir.20765","article-title":"Stereoselective metabolism of propranolol glucuronidation by human UDP-glucuronosyltransferases 2B7 and 1A9","volume":"22","author":"Yu","year":"2010","journal-title":"Chirality"},{"key":"10.1016\/j.fct.2023.114101_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.fct.2023.114101_bib44","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2147\/IDR.S170706","article-title":"Trough concentration of itraconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.fct.2023.114101_bib45","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/1535-7163.MCT-20-0638","article-title":"Itraconazole exerts its antitumor effect in esophageal cancer by suppressing the HER2\/AKT signaling pathway","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.fct.2023.114101_bib46","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1128\/AAC.01985-15","article-title":"Network meta-analysis and pharmacoeconomic evaluation of fluconazole, itraconazole, posaconazole, and voriconazole in invasive fungal infection prophylaxis","volume":"60","author":"Zhao","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.fct.2023.114101_bib47","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1124\/dmd.105.008631","article-title":"Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions","volume":"34","author":"Zhou","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.fct.2023.114101_bib48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome P450 enzymes and its clinical impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab. Rev."}],"container-title":["Food and Chemical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278691523005033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278691523005033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:13:33Z","timestamp":1736345613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278691523005033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":48,"alternative-id":["S0278691523005033"],"URL":"https:\/\/doi.org\/10.1016\/j.fct.2023.114101","relation":{},"ISSN":["0278-6915"],"issn-type":[{"value":"0278-6915","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro","name":"articletitle","label":"Article Title"},{"value":"Food and Chemical Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fct.2023.114101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114101"}}